Sensus Healthcare 2025 Q3 Earnings Sharp Earnings Decline with 185.7% EPS Drop

Sensus Healthcare (SRTS) reported a significant earnings downturn for Q3 2025, missing expectations with a net loss of $0.06 per share versus a $0.07 profit in the prior-year period. The company provided no formal revenue or EPS guidance, leaving analysts to assess risks like inflationary pressures and regulatory headwinds.

Revenue

Total revenue fell 22.1% year-over-year to $6.88 million in Q3 2025, driven by a contraction in both product and service segments. Product revenue accounted for the lion’s share at $5.36 million, while service revenue contributed $1.52 million. The decline reflects broader market challenges and operational headwinds.

Earnings/Net Income

Sensus Healthcare swung to a net loss of $943,000 in Q3 2025, a 177.6% deterioration from a $1.22 million profit in the prior-year period. Earnings per share plummeted 185.7% to a loss of $0.06, marking a stark reversal in profitability. This represents a significant negative performance for the quarter.

Price Action

The stock price of Sensus Healthcare exhibited mixed post-earnings activity, declining 4.70% during the latest trading day. However, it surged 26.70% over the most recent full trading week and gained 38.51% month-to-date, suggesting investor optimism amid short-term volatility.

CEO Commentary

Joe Sardano, Chairman and CEO, underscored Eric Sachetta’s strategic role in advancing SRT technology and global expansion. Highlighting Sachetta’s operational expertise, Sardano expressed confidence in the leadership team’s ability to navigate growth opportunities despite macroeconomic uncertainties.

Guidance

The company emphasized risks to future performance, including inflationary pressures, reimbursement dynamics, and competitive innovations. While no specific guidance was provided, Sensus Healthcare noted potential material deviations due to customer concentration and operational costs, as outlined in SEC filings.

Post-Earnings Price Action Review

Following the earnings release, Sensus Healthcare’s stock faced immediate downward pressure, with a 4.70% decline in a single trading day. This short-term drop contrasted with broader market optimism, as the stock rebounded sharply during the subsequent week, rising 26.70%. Month-to-date gains of 38.51% indicate resilience in investor sentiment despite the earnings miss. Analysts attribute the volatility to a mix of earnings underperformance and strategic positioning for long-term growth initiatives.

Additional News

On November 13, 2025, Michael Sardano, President of Sensus Healthcare, disclosed the purchase of 2,000 shares at $4.26 each, totaling $8,523. The transaction, reported via a Form 4/A filing, reflects insider confidence in the company’s near-term prospects. Sardano’s indirect holdings now total 118,839 shares. The purchase occurred just hours after the earnings report, signaling alignment between leadership and shareholder interests amid a challenging quarterly performance.

Guidance

The company’s forward-looking statements caution risks impacting future performance, including inflationary pressures, reimbursement levels, regulatory challenges, and competitive innovations. While no specific revenue or EPS guidance is provided, the release notes uncertainties around customer concentration, global market dynamics, and operational costs. The company acknowledges potential material deviations from expectations due to these factors, as outlined in prior SEC filings.